Junci Investment
VC Fund
Shanghai, China
Junci Investment is a PE firm focused on late stage investments in the big health and developed science and technology sectors.
- Total investments:
- 21
- Last investment:
- Lead investor:
- 5%
Last updated:
For AI agents: llms.txt
Industries Junci Investment invests in
Stages Junci Investment invests in
Countries Junci Investment invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bing Jiang
|
|||
Liying Zhang
|
|||
Investment Focus
Industry
- Medical 6 (29%)
- Health Care 6 (29%)
- Information Technology 4 (19%)
- Artificial Intelligence 4 (19%)
- Software 3 (14%)
Stage
- Private Equity 8 (38%)
- Series C 5 (24%)
- Series B 2 (10%)
- Series D 2 (10%)
- Series A 1 (5%)
Country
- China 15 (71%)
- United States 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Bing Jiang
Partner
|
Partner | Total investments: 0 | Find email | |
|
Liying Zhang
Partner
|
Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Emotibot Technologies
|
Emotibot Technologies designs and develops emotional intelligence systems for robots.The company provides robots with multi-modal emotion recognition and machine learning platforms. The systems offer humanized conversations, vision understanding, and affective computing. The systems can be used in mobile devices, speakers, homes, automobiles,wearables, and headsets.Emotibot was founded in 2015 by Kenny Chien and is based in Shanghai. | Series D / Feb 27, 2023 | |
|
Emotibot Technologies
|
Emotibot Technologies designs and develops emotional intelligence systems for robots.The company provides robots with multi-modal emotion recognition and machine learning platforms. The systems offer humanized conversations, vision understanding, and affective computing. The systems can be used in mobile devices, speakers, homes, automobiles,wearables, and headsets.Emotibot was founded in 2015 by Kenny Chien and is based in Shanghai. | $13.4M / Series D / Jul 11, 2022 | |
Singlera
|
Singlera is a medical firm that is working to overcome the delay in early diagnosis of cancer through screening and auxiliary. | $44.9M / Series B / Jun 08, 2022 | |
Singlera Genomics
|
Singlera Genomics is a fast growing company focusing on non-invasive genetic testing. Singlera’s main products and services include tumor diagnosis and personalized treatment, non-invasive prenatal diagnosis, pre-implantation genetic screening, and customized scientific research services. Singlera is dedicated to the development of precisionmedicine, striving to help the patients through early, accurate and informative diagnoses. | $44.9M / Series B / Jun 08, 2022 | |
Chinagene Tech
|
Beijing Zhongyin Technology Co., Ltd. is a professional enterprise engaged in the research and development of clinical genetic diagnosis, prevention and gene therapy for hereditary eye diseases. The company's clinical genetic diagnosis platform for hereditary eye diseases can provide fast, accurate, reliable and professional clinical geneticdiagnosis services for hereditary ophthalmology patients. | $15.8M / Series A / Mar 30, 2022 | |
|
Singlera Genomics
|
Singlera Genomics is a fast growing company focusing on non-invasive genetic testing. Singlera’s main products and services include tumor diagnosis and personalized treatment, non-invasive prenatal diagnosis, pre-implantation genetic screening, and customized scientific research services. Singlera is dedicated to the development of precisionmedicine, striving to help the patients through early, accurate and informative diagnoses. | Private Equity / Aug 01, 2021 | |
|
Emotibot Technologies
|
Emotibot Technologies designs and develops emotional intelligence systems for robots.The company provides robots with multi-modal emotion recognition and machine learning platforms. The systems offer humanized conversations, vision understanding, and affective computing. The systems can be used in mobile devices, speakers, homes, automobiles,wearables, and headsets.Emotibot was founded in 2015 by Kenny Chien and is based in Shanghai. | Private Equity / Aug 01, 2021 | |
LeiShen Intelligent System
|
LeiShen Intelligent System Co., LTD which is acknowledged as a national leader in LIDAR industry is devoted to provide advanced products including LiDAR products for robots navigation and anti-collision, laser imaging sensor, obstacle-avoidance LiDAR for self-driving vehicles, altitude-hold LiDAR for laser scanners, displace sensors, specialrobots, special fiber lasers, 1064nm high-power consecutive-pulse fiber laser, fiber devices, etc. and relevant solutions. LeiShen has long been valuing core technologies, and developing under world-class strategic insight and excellent Innovation. LeiShen intends to make Human Life better with science and technology. By far, LeiShen Team has obtained 58 patents, 17 software copyrights, and has submitted 100 patent claims, 43 of which are patents for invention. Moreover, LeiShen has acquired certificate of ISO quality management system. In 2015, 4 technology patents have been carried forward into production. And a number of their core technologies have reached the leading level in the world. Among the laser scanner products, series for cleaning robots and service robots have been put into mass production. These laser scanners are developed based on triangulation principle and matched with relevant SLAM algorithms, and stand strong sunlight up to 70,000 lux, and also have ultra-long service life-time and strong reliability, leading industry level. Moreover, the new-generation creative non-rotating laser scanner is perfect for altitude-hold , industrial automation, etc. In addition, 2D TOF laser scanners have been successfully developed. | $46.5M / Series C / Jul 29, 2021 | |
Geneplus-Beijing Co. Ltd.
|
Provider of gene sequencing and detection solutions used in cancer research and treatment. | $106.3M / Series C / Jul 22, 2021 | |
Gene+
|
Beijing Gene+, also known as Beijing Gene Plus, provides gene testing services for cancer prevention, early detection, as well as providing data for the implementation of precision medicine. The company claims to operate in around 100 hospitals and have served thousands of cancer patients in China. | $115.9M / Series C / Jul 22, 2021 | |
| See all 21 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Junci Investment invest in?
Junci Investment invests primarily in Medical, Health Care and Information Technology startups, most often at Private Equity and Series C stage. Most of the 21 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Junci Investment?
Public channels for Junci Investment include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Junci Investment?
The team at Junci Investment includes Bing Jiang (Partner) and Liying Zhang (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
